The new collaboration has been signed between AbbVie and Voyager Therapeutics and will focus on the development of gene therapies consisting of vectors to deliver monoclonal antibodies to the brain directed against tau-protein for the treatment of Alzheimer’s and other neurodegenerative diseases. Tau is an abundant protein in the brain that promotes cellular stability and function. It progressively accumulates during the disease, resulting in impaired brain function and neuronal cell loss.